Life Molecular Imaging — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Life Molecular Imaging is a commercial-stage diagnostics company acquired by Lantheus in 2025, originating from Bayer's R&D portfolio. Its core business is developing and supplying innovative PET tracers, with its flagship product, Neuraceq® (florbetaben F18), approved for beta-amyloid imaging in Alzheimer's disease evaluation. The company operates a global supply network for clinical trials and commercial use, with a pipeline targeting next-generation tracers for Tau, MAO-B, and cardiac amyloidosis. Its model integrates proprietary tracer development with pharma collaboration services.

NeuroscienceCardiology

Technology Platform

Development and commercialization of targeted Positron Emission Tomography (PET) radiopharmaceuticals for imaging specific disease biomarkers in neurology and cardiology.

Opportunities

The rapid growth of the Alzheimer's disease diagnostics market, fueled by new disease-modifying therapies requiring amyloid and tau PET confirmation, presents a major near-term opportunity.

Long-term, the pipeline in cardiac amyloidosis and neuroinflammation addresses large, underserved markets with growing therapeutic innovation.

Risk Factors

Intense competition in the PET tracer space from larger pharmaceutical and imaging companies could pressure market share.

Pipeline progression risks include clinical trial failures for next-generation tracers.

Market adoption remains heavily dependent on favorable and stable reimbursement policies from global payers.

Competitive Landscape

LMI competes in the amyloid PET market with Eli Lilly's Amyvid and GE Healthcare's Vizamyl. In the emerging tau PET space, it faces competition from late-stage programs by Eli Lilly and others. As part of Lantheus, it now competes within the broader radiopharmaceutical landscape against companies like GE HealthCare, Curium, and Novartis.

More companies in Diagnostics & Precision Medicine →More companies in Germany →